High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
| (17 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
{| style="font-size:120%" | {| style="font-size:120%" | ||
|- | |- | ||
| [[CHI | | [[The CHI SQUARE Trial]] | ||
|- | |- | ||
| [[ | | [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]] | ||
|- | |||
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]] | |||
|- | |- | ||
| [[CSL-112 Trial - Phase 2a]] | | [[CSL-112 Trial - Phase 2a]] | ||
| Line 23: | Line 25: | ||
| [[ACCELERATE Trial]] | | [[ACCELERATE Trial]] | ||
|- | |- | ||
| [[ | | [[Dal-OUTCOMES Trial]] | ||
|- | |||
| [[Dal-VESSEL Trial]] | |||
|- | |||
| [[Dal-PLAQUE Trial]] | |||
|- | |- | ||
| [[DEFINE Trial]] | | [[DEFINE Trial]] | ||
| Line 32: | Line 38: | ||
|- | |- | ||
| [[REVEAL Trial]] | | [[REVEAL Trial]] | ||
|- | |||
| [[REVEAL HPS-3 TIMI-55 trial]] | |||
|- | |||
| [[RADIANCE 1]] | |||
|- | |||
| [[RADIANCE 2]] | |||
|- | |- | ||
|} | |} | ||
| Line 51: | Line 63: | ||
|- | |- | ||
| [[Oxford Niaspan Study]] | | [[Oxford Niaspan Study]] | ||
|- | |||
| [[Coronary Drug Project]] | |||
|- | |||
| [[Stockholm Ischemic Heart Disease Study]] | |||
|- | |||
| [[FATS]] | |||
|- | |||
| [[UCSF-SCOR]] | |||
|- | |- | ||
|} | |} | ||
| Line 62: | Line 82: | ||
|- | |- | ||
| [[BIP Trial]] | | [[BIP Trial]] | ||
|- | |||
| [[Helsinki Heart Study]] | |||
|- | |||
| [[DAIS]] | |||
|- | |||
| [[FIELD]] | |||
|- | |- | ||
|} | |} | ||
| Line 93: | Line 119: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Lipoproteins]] | [[Category:Lipoproteins]] | ||
[[Category:HDLpedia]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 02:41, 19 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein landmark trials On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
|
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Reconstituted HDL Infusion
CETP Inhibitors
| ACCELERATE Trial |
| Dal-OUTCOMES Trial |
| Dal-VESSEL Trial |
| Dal-PLAQUE Trial |
| DEFINE Trial |
| ILLUMINATE Trial |
| ILLUSTRATE Trial |
| REVEAL Trial |
| REVEAL HPS-3 TIMI-55 trial |
| RADIANCE 1 |
| RADIANCE 2 |
Niacin
| AIM-HIGH Trial |
| ARBITER 2 Trial |
| ARBITER 3 Trial |
| ARBITER 6-HALTS Trial |
| CLAS Trial |
| HATS Trial |
| Oxford Niaspan Study |
| Coronary Drug Project |
| Stockholm Ischemic Heart Disease Study |
| FATS |
| UCSF-SCOR |
Fibrate
| VA-HIT Trial |
| BECAIT Trial |
| BIP Trial |
| Helsinki Heart Study |
| DAIS |
| FIELD |
Statin
| ASTEROID Trial |
| SATURN Trial |
| 4S Trial |
| CORONA Trial |
Multiple Lipid Lowering Drugs
| HARP Study |
| AFREGS Trial |